Literature DB >> 21960772

Step-up versus top-down therapy in the treatment of ulcerative colitis.

William J Sandborn1.   

Abstract

Entities:  

Year:  2007        PMID： 21960772      PMCID： PMC3096114     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  4 in total

1.  Infliximab for induction and maintenance therapy for ulcerative colitis.

Authors:  Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

Review 2.  Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.

Authors:  William J Sandborn
Journal:  Rev Gastroenterol Disord       Date:  2006

Review 3.  What's new: innovative concepts in inflammatory bowel disease.

Authors:  W J Sandborn
Journal:  Colorectal Dis       Date:  2006-05       Impact factor: 3.788

4.  Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine.

Authors:  Sierra Matula; Victoria Croog; Steven Itzkowitz; Noam Harpaz; Carol Bodian; Sabera Hossain; Thomas Ullman
Journal:  Clin Gastroenterol Hepatol       Date:  2005-10       Impact factor: 11.382
  4 in total
  7 in total

Review 1.  When combination therapy isn't working: emerging therapies for the management of inflammatory bowel disease.

Authors:  Suneeta Krishnareddy; Arun Swaminath
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

Review 2.  Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults.

Authors:  Gerda C Leitner; Harald Vogelsang
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

Review 3.  Review article: the pathogenesis of pouchitis.

Authors:  K M Schieffer; E D Williams; G S Yochum; W A Koltun
Journal:  Aliment Pharmacol Ther       Date:  2016-08-24       Impact factor: 8.171

Review 4.  JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines.

Authors:  Silvio Danese; Matthew Grisham; Jennifer Hodge; Jean-Baptiste Telliez
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-11-25       Impact factor: 4.052

5.  Association of Preoperative Anti-Tumor Necrosis Factor Therapy With Adverse Postoperative Outcomes in Patients Undergoing Abdominal Surgery for Ulcerative Colitis.

Authors:  Audrey S Kulaylat; Afif N Kulaylat; Eric W Schaefer; Andrew Tinsley; Emmanuelle Williams; Walter Koltun; Christopher S Hollenbeak; Evangelos Messaris
Journal:  JAMA Surg       Date:  2017-08-16       Impact factor: 14.766

6.  Biologic treatment of Japanese patients with inflammatory bowel disease.

Authors:  Jörg Mahlich; Katsuyoshi Matsuoka; Rosarin Sruamsiri
Journal:  BMC Gastroenterol       Date:  2018-11-01       Impact factor: 3.067

7.  Effect of a bioactive product SEL001 from Lactobacillus sakei probio65 on gut microbiota and its anti-colitis effects in a TNBS-induced colitis mouse model.

Authors:  Irfan A Rather; Vivek K Bajpai; Lew L Ching; Rajib Majumder; Gyeong-Jun Nam; Nagaraju Indugu; Prashant Singh; Sanjay Kumar; Nahid H Hajrah; Jamal S M Sabir; Majid Rasool Kamli; Yong-Ha Park
Journal:  Saudi J Biol Sci       Date:  2019-09-04       Impact factor: 4.219
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.